Abstract 433P
Background
An estimated 70-80% of malignancies need multimodal treatment, which includes surgery, radiation, and chemotherapy. Radiation oncology is particularly vulnerable to regional disparities in access to care due to the unique nature of its treatments.It is vital to define geographic and demographic access to radiotherapy in order to improve patient access to clinical care.This first of its kind study aimed at quantifying the available radiation oncology resources across all Asian counties.
Methods
The availability of Teletherapy and Brachytherapy resources of all Asian Countries was obtained from IAEA-DIRAC. The population o was estimated using World Bank Population Estimates. The incidence of cancers was obtained from Globocan Reports.Available number of treatment units were compared with that of the population, overall cancer incidence and five most common cancers among countries across Asia. Total EBRT treatment capacity was estimated by multiplying the number of units per country with 240 working days. Assuming that 50 patients would be treated per day, a proportional treatment space of 15% was estimated for Breast and lung cancers and, 10% each for stomach, cervical and oesophageal cancers. Therefore, feasible fractions were estimated as: number of EBRT units per country × 240 × (0.15 or 0.10) × 50. Number of excess or deficit fractions were calculated, and the total number of extra machines required was arrived at.
Results
Number of teletherapy units varied from 1 to 1825 across countries. Yemen had the least number of teletherapy units per million population (0.03) whereas Japan had the highest (8.66). Brunei had 1 teletherapy machine per 493 cancer cases whereas North Korea had 1 machine per 19218 cases. Qatar had 1 brachytherapy machine for 1482 cancer cases and Taiwan had 1 Brachytherapy machine for 55483 cancer cases.41 countries had a deficit in number of teletherapy machines with respect to breast cancer. Similarly, 33, 28, 32 and 18 countries had a deficit with respect to lung, stomach, cervical and oesophageal cancers respectively.
Conclusions
The study identified deficits of radiotherapy units in terms of geographic and demographic aspect across Asian countries and provides a roadmap for development of radiation oncology infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06